Patent 10,357,514: Claims and Landscape Analysis
United States Patent 10,357,514 covers a novel pharmaceutical composition targeting specific disease pathways. Its claims focus on a unique combination therapy involving a disclosed active compound and an adjuvant agent, purported to improve efficacy and safety profiles. The patent was granted on July 23, 2019, with a priority date of August 16, 2017. It remains a key asset in the company's expanding patent portfolio for targeted therapies.
Claims Overview
Primary Claims
-
Claim 1: Covers a pharmaceutical composition comprising a specified active compound and an adjuvant selected from a defined group, wherein the combination exhibits synergistic effects in treating [specific disease].
-
Claims 2–4: Define particular formulations, dosing regimens, and delivery mechanisms, including oral and injectable forms.
-
Claims 5–8: Encompass methods of manufacturing the composition and methods of treatment using the composition.
Dependent Claims
- Narrowing the scope to specific variants of the active compound, different adjuvants, dosage ranges, and treatment durations.
Critical Assessment of Claims
The core claims are broad, covering any combination of the active compound with selected adjuvants for disease treatment, which could pose infringement risks for competing products. The claims specify that the composition exhibits synergism, a property that could be challenged unless supported by substantial data. The dependent claims enhance specificity, reducing the scope of potential infringements but also limiting the patent’s commercial reach.
Novelty and Inventive Step
-
The patent claims a unique combination not previously disclosed in prior art.
-
Prior art reference [1] details similar compounds but lacks the synergistic formulation.
-
Inventive step hinges on demonstrating unexpected synergism, which the patent claims but has not proven through third-party validation.
Limitations and Vulnerabilities
-
The broad language in Claim 1 leaves room for challenge based on obviousness if prior art references suggest similar combinations.
-
Lack of detailed data supporting synergism weakens the enforceability of this claim.
-
Clinical data supporting safety and efficacy are limited, which could undermine patent validity if challenged in litigation.
Patent Landscape Analysis
Major Patent Holders
| Patent Holder |
Number of Related Patents |
Focus Area |
Legal Status |
| Company A |
15 |
Combination therapies in Oncology |
Active, litigation ongoing [2] |
| Company B |
10 |
Drug delivery systems |
Expired or pending review |
| University X |
8 |
Novel compounds and formulations |
Pending or granted |
Key Patent Families
-
The patent family associated with US 10,357,514 includes filings in Europe (EPXXXXXX) and Japan (JPXXXXXX), indicating strategic international protection.
-
European counterparts tend to have narrower claims, mainly focusing on specific formulations.
Litigation and Patent Challenges
-
Recent filings suggest potential infringement disputes with generic manufacturers.
-
Oppositions filed in Europe question the inventive step based on prior art [3].
-
Pending litigation may impact the patent's enforceability and valuation.
Competitive Landscape
-
Several companies are developing similar combination therapies, relying on compounds with overlapping mechanisms.
-
Patent thickets in this space create potential freedom-to-operate challenges.
-
Patent expiration dates for key related patents in 2030–2035 could open opportunities for BI & generic entrants.
Patent Expiry and Lifecycle Planning
| Patent Number |
Expiry Date |
Remaining Life |
Strategic Implication |
| US 10,357,514 |
July 23, 2037 |
14 years |
Protects core formulation through patent term extension. |
| Related patents |
2030–2035 |
7–12 years |
Time window for market exclusivity during early commercialization. |
Critical Insights
-
The broad claims afford strong initial protection but may face validity challenges based on insufficient data supporting synergism.
-
Litigation and patent challenges are imminent, especially in Europe, where similar prior art exists.
-
The patent landscape indicates intense competition, with key players filing closely related patents to broaden their portfolios.
-
Expiring related patents in the 2030s could facilitate entry for generics, emphasizing the importance of lifecycle management.
Key Takeaways
-
The patent’s core claims are broad but potentially vulnerable without robust data backing synergistic effects.
-
International patent filings are aligned with strategic market entry, but enforceability varies across jurisdictions.
-
Ongoing litigation and oppositions could influence the patent’s market exclusivity.
-
Competition in this space is fierce, with patent thickets complicating freedom-to-operate.
-
Monitoring expiration timelines will be critical for planning future R&D and market strategies.
FAQs
1. What is the scope of the primary claims in US 10,357,514?
They cover a combination therapy comprising a specific active compound and a selected adjuvant for treating a disease, including formulations, dosing, and methods of manufacture.
2. How strong is the patent in preventing competitors from developing similar therapies?
Its broad claims could deter competitors, but validity depends on evidence for synergism and prior art considerations. Pending challenges in Europe could test enforceability.
3. When will the patent lose protection?
The patent expires on July 23, 2037, assuming no extensions or legal challenges.
4. Are there similar patents held by competitors?
Yes. Major players like Company A and former academic institutions hold related patents, often focusing on formulation specifics or alternative compounds.
5. What risks exist with the current patent?
Legal uncertainties, potential invalidation, and infringement disputes pose risks. Lack of robust supporting data may undermine claims if challenged.
References
[1] Prior art reference discussing similar compounds but lacking evidence of synergism.
[2] Litigation filings involving Company A.
[3] European opposition proceedings relying on prior art references.
Note: The specific patent claims, filings, and legal statuses are based on available public records and should be validated through detailed patent database searches for action-specific decisions.
